litlas
Log inCreate account

Thomas M. Habermann

Active 1983–2025

Also published as
Thomas M Habermann
194
Papers
31,493
Citations
99
h-index
184
i10-index

Citations

Citations per year for Thomas M. Habermann1984: 1 citations1985: 3 citations1986: 1 citations1987: 1 citations1988: 4 citations1989: 2 citations1990: 1 citations1991: 3 citations1992: 5 citations1993: 3 citations1994: 3 citations1995: 3 citations1996: 3 citations1997: 9 citations1998: 14 citations1999: 18 citations2000: 25 citations2001: 42 citations2002: 49 citations2003: 60 citations2004: 46 citations2005: 98 citations2006: 113 citations2007: 120 citations2008: 152 citations2009: 165 citations2010: 205 citations2011: 193 citations2012: 213 citations2013: 270 citations2014: 275 citations2015: 278 citations2016: 295 citations2017: 279 citations2018: 275 citations2019: 947 citations2020: 1,012 citations2021: 956 citations2022: 699 citations2023: 451 citations2024: 823 citations2025: 308 citations2026: 10 citations

Citation sources

Countries

World map of the countries and regions citing this authorUnited States: 3,350 citing papers, 29.5% of this breakdownGermany: 702 citing papers, 6.2% of this breakdownUnited Kingdom: 698 citing papers, 6.2% of this breakdownChina: 673 citing papers, 5.9% of this breakdownFrance: 619 citing papers, 5.5% of this breakdownItaly: 610 citing papers, 5.4% of this breakdownCanada: 528 citing papers, 4.7% of this breakdownSpain: 394 citing papers, 3.5% of this breakdownSwitzerland: 371 citing papers, 3.3% of this breakdownAustralia: 297 citing papers, 2.6% of this breakdownNetherlands: 255 citing papers, 2.2% of this breakdownJapan: 250 citing papers, 2.2% of this breakdown
0%29.5%Other 22.8%

Institutions

Fields

  • Medicine71.6%
  • Biochemistry, Genetics and Molecular Biology11%
  • Health Professions8.9%
  • Immunology and Microbiology4.4%
  • Psychology1.2%
  • Nursing0.8%
  • Other2.1%

Topics

  • Lymphoma Diagnosis and Treatment15.8%
  • Chronic Lymphocytic Leukemia Research6.5%
  • Viral-associated cancers and disorders5.3%
  • CAR-T cell therapy research4.6%
  • CNS Lymphoma Diagnosis and Treatment3.8%
  • Healthcare professionals’ stress and burnout3.2%
  • Other60.8%

Coauthors

All papers

Open in search
  1. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes

    Authors: Bjoern Chapuy, Chip Stewart, Andrew Dunford, Jaegil Kim, Atanas Kamburov, Robert Redd, Mike S. Lawrence, Margaretha G.M. Roemer, Amy J. Li, Marita Ziepert, Annette M. Staiger, Jeremiah A. Wala, Matthew D. Ducar, Ignaty Leshchiner, Ester Rheinbay, Amaro Taylor‐Weiner, Caroline A. Coughlin, Julian M. Hess, Chandra Sekhar Pedamallu, Dimitri Livitz, Daniel Rosebrock, Mara Rosenberg, Adam Tracy, Heike Horn, Paul Van Hummelen, Andrew L. Feldman, Brian K. Link, Anne J. Novak, James R. Cerhan, Thomas M. Habermann, Reiner Siebert, Andreas Rosenwald, Aaron R. Thorner, Matthew Meyerson, Todd R. Golub, Rameen Beroukhim, Gerald Wulf, German Ott, Scott J. Rodig, Stefano Monti, Donna Neuberg, Markus Loeffler, Michael Pfreundschuh, Lorenz Trümper, Gad Getz, Margaret A. Shipp - Nature Medicine 2018 cited by 1,972

  2. Targeting B cell receptor signaling with ibrutinib in diffuse large B cell lymphoma

    Authors: Wyndham H. Wilson, Ryan M. Young, Roland Schmitz, Yandan Yang, Stefania Pittaluga, George W. Wright, Chih-Jian Lih, P. Mickey Williams, Arthur L. Shaffer, John F. Gerecitano, Sven de Vos, André Goy, Vaishalee P. Kenkre, Paul M. Barr, Kristie A. Blum, Andrei R. Shustov, Ranjana H. Advani, Nathan Fowler, Julie M. Vose, Rebecca Elstrom, Thomas M. Habermann, Jacqueline C. Barrientos, Jesse McGreivy, Maria Fardis, Betty Chang, Fong Clow, Brian Munneke, Davina Moussa, Darrin M. Beaupre, Louis M. Staudt - Nature Medicine 2015 cited by 1,110

  3. Association of Perceived Medical Errors With Resident Distress and Empathy

    Authors: Colin P. West, Mashele Huschka, Paul J. Novotny, Jeff A. Sloan, Joseph C. Kolars, Thomas M. Habermann, Tait D. Shanafelt - JAMA 2006 cited by 1,457

  4. Pembrolizumab in patients with CLL and Richter transformation or with relapsed CLL

    Authors: Wei Ding, Betsy LaPlant, Timothy G. Call, Sameer A. Parikh, José F. Leis, Rong He, Tait D. Shanafelt, Sutapa Sinha, Jennifer Le‐Rademacher, Andrew L. Feldman, Thomas M. Habermann, Thomas E. Witzig, Gregory A. Wiseman, Yi Lin, Erik Asmus, Grzegorz S. Nowakowski, Michael Conte, Deborah A. Bowen, Casey N. Aitken, Daniel L. Van Dyke, Patricia T. Greipp, Xin Liu, Xiaosheng Wu, Henan Zhang, Charla Secreto, Shulan Tian, Esteban Braggio, Linda Wellik, Ivana N. Micallef, David S. Viswanatha, Huihuang Yan, Asher Chanan‐Khan, Neil E. Kay, Haidong Dong, Stephen M. Ansell - Blood 2017 cited by 412

  5. Event-Free Survival at 24 Months Is a Robust End Point for Disease-Related Outcome in Diffuse Large B-Cell Lymphoma Treated With Immunochemotherapy

    Authors: Matthew J. Maurer, Hervé Ghesquières, Jean‐Philippe Jais, Thomas E. Witzig, Corinne Haïoun, Carrie A. Thompson, Richard Delarue, Ivana N. Micallef, Frédéric Peyrade, William R. Macon, Thierry Jo Molina, Nicolas Ketterer, Sergei Syrbu, Olivier Fitoussi, Paul J. Kurtin, Cristine Allmer, Emmanuelle Nicolas‐Virelizier, Susan L. Slager, Thomas M. Habermann, Brian K. Link, Gilles Salles, Hervé Tilly, James R. Cerhan - Journal of Clinical Oncology 2014 cited by 410

  6. Discovery and prioritization of somatic mutations in diffuse large B-cell lymphoma (DLBCL) by whole-exome sequencing

    Authors: Jens G. Lohr, Petar Stojanov, Michael S. Lawrence, Daniel Auclair, Bjoern Chapuy, Carrie Sougnez, Peter Cruz‐Gordillo, Birgit Knoechel, Yan W. Asmann, Susan L. Slager, Anne J. Novak, Ahmet Doǧan, Stephen M. Ansell, Brian K. Link, Lihua Zou, Joshua Gould, Gordon Saksena, Nicolas Stransky, Claudia Rangel‐Escareño, Juan Carlos Fernández-López, Alfredo Hidalgo‐Miranda, Jorge Meléndez-Zajgla, Enrique Hernández–Lemus, Angela Schwarz‐Cruz y Celis, Iván Imaz-Rosshandler, Akinyemi I. Ojesina, Joonil Jung, Chandra Sekhar Pedamallu, Eric S. Lander, Thomas M. Habermann, James R. Cerhan, Margaret A. Shipp, Gad Getz, Todd R. Golub - National Academy of Sciences, Proceedings of the National Academy of Sciences 2012 cited by 980

  7. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 6.2023

    Authors: Andrew D. Zelenetz, Leo I. Gordon, Jeremy S. Abramson, Ranjana H. Advani, B. Andreadis, Nancy L. Bartlett, Lihua E. Budde, Paolo F. Caimi, Julie Chang, Beth Christian, Sven deVos, Bhagirathbhai Dholaria, Luis Fayad, Thomas M. Habermann, Muhammad Saad Hamid, Francisco J. Hernandez‐Ilizaliturri, Boyu Hu, Mark Kaminski, Yasmin Karimi, Chris R. Kelsey, Rebecca L. King, Susan Krivacic, Ann S. LaCasce, Megan S. Lim, Marcus Messmer, Mayur Narkhede, Rachel Rabinovitch, Praveen Ramakrishnan, Erin Reid, Kenneth B. Roberts, Hayder Saeed, Stephen D. Smith, Jakub Svoboda, Lode J. Swinnen, Joseph M. Tuscano, Julie M. Vose, Mary A. Dwyer, Hema Sundar - Journal of the National Comprehensive Cancer Network 2023 cited by 117

  8. Rituximab-CHOP Versus CHOP Alone or With Maintenance Rituximab in Older Patients With Diffuse Large B-Cell Lymphoma

    Authors: Thomas M. Habermann, Edie Weller, Vicki A. Morrison, Randy D. Gascoyne, Peter A. Cassileth, Jeffrey Cohn, Shaker R. Dakhil, Bruce A. Woda, Richard I. Fisher, B. A. Peterson, Sandra J. Horning - Journal of Clinical Oncology 2006 cited by 1,367

  9. Post-Transplantation Lymphoproliferative Disorders in Adults

    Authors: Daan Dierickx, Thomas M. Habermann - New England Journal of Medicine 2018 cited by 464

  10. ALK-negative anaplastic large cell lymphoma is a genetically heterogeneous disease with widely disparate clinical outcomes

    Authors: Edgardo R. Parrilla Castellar, Elaine S. Jaffe, Jonathan Said, Steven H. Swerdlow, Rhett P. Ketterling, Ryan A. Knudson, Jagmohan S. Sidhu, Eric D. Hsi, Shridevi Karikehalli, Liuyan Jiang, George Vasmatzis, Sarah E. Gibson, Sarah L. Ondrejka, Alina Nicolae, Karen L. Grogg, Cristine Allmer, Kay M. Ristow, Wyndham H. Wilson, William R. Macon, Mark E. Law, James R. Cerhan, Thomas M. Habermann, Stephen M. Ansell, Ahmet Doǧan, Matthew J. Maurer, Andrew L. Feldman - Blood 2014 cited by 466

  11. Rates and Outcomes of Follicular Lymphoma Transformation in the Immunochemotherapy Era: A Report From the University of Iowa/Mayo Clinic Specialized Program of Research Excellence Molecular Epidemiology Resource

    Authors: Brian K. Link, Matthew J. Maurer, Grzegorz S. Nowakowski, Stephen M. Ansell, William R. Macon, Sergei Syrbu, Susan L. Slager, Carrie A. Thompson, David J. Inwards, Patrick B. Johnston, Joseph P. Colgan, Thomas E. Witzig, Thomas M. Habermann, James R. Cerhan - Journal of Clinical Oncology 2013 cited by 332

  12. Cause of Death in Follicular Lymphoma in the First Decade of the Rituximab Era: A Pooled Analysis of French and US Cohorts

    Authors: Clémentine Sarkozy, Matthew J. Maurer, Brian K. Link, Hervé Ghesquières, Émmanuelle Nicolas, Carrie A. Thompson, Alexandra Traverse‐Glehen, Andrew L. Feldman, Cristine Allmer, Susan L. Slager, Stephen M. Ansell, Thomas M. Habermann, Emmanuel Bachy, James R. Cerhan, Gilles Salles - Journal of Clinical Oncology 2018 cited by 239

  13. Non‐Hodgkin lymphoma subtype distribution, geodemographic patterns, and survival in the US: A longitudinal analysis of the National Cancer Data Base from 1998 to 2011

    Authors: Mohammed Al‐Hamadani, Thomas M. Habermann, James R. Cerhan, William R. Macon, Matthew J. Maurer, Ronald S. Go - American Journal of Hematology 2015 cited by 280

  14. Lack of intrafollicular memory CD4 + T cells is predictive of early clinical failure in newly diagnosed follicular lymphoma

    Authors: Patrizia Mondello, Angelo Famà, Melissa C. Larson, Andrew L. Feldman, José C. Villasboas, Zhi-Zhang Yang, Ilia Galkin, Viktor Svelolkin, Ekaterina Postovalova, Alexander Bagaev, Pavel Ovcharov, Arina Varlamova, Sarah Huet, Bruno Tesson, Kaitlyn McGrath, Susan L. Slager, Brian K. Link, Sergei Syrbu, Anne J. Novak, Thomas M. Habermann, Thomas E. Witzig, Grzegorz S. Nowakowski, Gilles Salles, James R. Cerhan, Stephen M. Ansell - Blood Cancer Journal 2021 cited by 66

  15. Treatment patterns and outcomes of patients with relapsed or refractory follicular lymphoma receiving three or more lines of systemic therapy (LEO CReWE): a multicentre cohort study

    Authors: Carla Casulo, Melissa C. Larson, Julianne J. Lunde, Thomas M. Habermann, Izidore S. Lossos, Yucai Wang, Loretta J. Nastoupil, Christopher Strouse, Dai Chihara, Peter Martin, Jonathon B. Cohen, Brad S. Kahl, Richard Burack, Jean L. Koff, Yong Mun, Anthony Masaquel, Mei Wu, Michael C. Wei, Ashwini Shewade, Jia Li, James R. Cerhan, Christopher R. Flowers, Brian K. Link, Matthew J. Maurer - The Lancet Haematology 2022 cited by 63

  16. Phase I Study of Ipilimumab, an Anti–CTLA-4 Monoclonal Antibody, in Patients with Relapsed and Refractory B-Cell Non–Hodgkin Lymphoma

    Authors: Stephen M. Ansell, Sara A. Hurvitz, Patricia Koenig, Betsy LaPlant, Brian Kabat, Donna Fernando, Thomas M. Habermann, David J. Inwards, Meena Verma, Reiko Yamada, Charles Erlichman, Israel Lowy, John M. Timmerman - Clinical Cancer Research 2009 cited by 332

  17. Epidemiology of marginal zone lymphoma

    Authors: James R. Cerhan, Thomas M. Habermann - Annals of Lymphoma 2021 cited by 123

  18. The well-being of physicians

    Authors: Tait D. Shanafelt, Jeff A. Sloan, Thomas M. Habermann - The American Journal of Medicine 2003 cited by 792

  19. NCCN Guidelines® Insights: B-Cell Lymphomas, Version 5.2021

    Authors: Andrew D. Zelenetz, Leo I. Gordon, Julie Chang, Beth Christian, Jeremy S. Abramson, Ranjana H. Advani, Nancy L. Bartlett, Lihua E. Budde, Paolo F. Caimi, Sven de Vos, Bhagirathbhai Dholaria, Bita Fakhri, Luis Fayad, Martha Glenn, Thomas M. Habermann, Francisco J. Hernandez‐Ilizaliturri, Eric D. Hsi, Boyu Hu, Mark Kaminski, Chris R. Kelsey, Nadia Khan, Susan Krivacic, Ann S. LaCasce, Megan S. Lim, Mayur Narkhede, Rachel Rabinovitch, Praveen Ramakrishnan, Erin Reid, Kenneth B. Roberts, Hayder Saeed, Stephen D. Smith, Jakub Svoboda, Lode J. Swinnen, Joseph M. Tuscano, Julie M. Vose, Mary A. Dwyer, Hema Sundar - Journal of the National Comprehensive Cancer Network 2021 cited by 170

  20. Cohort Profile: The Lymphoma Specialized Program of Research Excellence (SPORE) Molecular Epidemiology Resource (MER) Cohort Study

    Authors: James R. Cerhan, Brian K. Link, Thomas M. Habermann, Matthew J. Maurer, Andrew L. Feldman, Sergei Syrbu, Carrie A. Thompson, Umar Farooq, Anne J. Novak, Susan L. Slager, Cristine Allmer, Julianne J. Lunde, William R. Macon, David J. Inwards, Patrick B. Johnston, Ivana N. Micallef, Grzegorz S. Nowakowski, Stephen M. Ansell, Neil E. Kay, George J. Weiner, Thomas E. Witzig - International Journal of Epidemiology 2017 cited by 90

  21. Diffuse large B‐cell lymphoma (Richter syndrome) in patients with chronic lymphocytic leukaemia (CLL): a cohort study of newly diagnosed patients

    Authors: Sameer A. Parikh, Kari G. Rabe, Timothy G. Call, Clive S. Zent, Thomas M. Habermann, Wei Ding, José F. Leis, Susan M. Schwager, Curtis A. Hanson, William R. Macon, Neil E. Kay, Susan L. Slager, Tait D. Shanafelt - British Journal of Haematology 2013 cited by 222

  22. A simplified scoring system in de novo follicular lymphoma treated initially with immunochemotherapy

    Authors: Emmanuel Bachy, Matthew J. Maurer, Thomas M. Habermann, Bénédicte Gelas‐Dore, Delphine Maucort‐Boulch, Jane Estell, Éric Van Den Neste, Réda Bouabdallah, Emmanuel Gyan, Andrew L. Feldman, Joan Bargay, Alain Delmer, Susan L. Slager, María Gomes da Silva, Olivier Fitoussi, David Belada, Hervé Maisonneuve, Tanin Intragumtornchai, Stephen M. Ansell, T. Lamy, Peggy Dartigues, Brian K. Link, John F. Seymour, James R. Cerhan, Gilles Salles - Blood 2018 cited by 206

  23. Pretransplant solid organ malignancy and organ transplant candidacy: A consensus expert opinion statement

    Authors: David Al‐Adra, Laura L. Hammel, John P. Roberts, E. Steve Woodle, Deborah J. Levine, Didier A. Mandelbrot, Elizabeth C. Verna, Jayme E. Locke, Jonathan D’Cunha, Maryjane Farr, Deirdre Sawinski, Piyush K. Agarwal, Jennifer K. Plichta, Sandhya Pruthi, Deborah Farr, Richard D. Carvajal, John Walker, Fiona O. Zwald, Thomas M. Habermann, Morie A. Gertz, Philip J. Bierman, Don S. Dizon, Carrie Langstraat, Talal Al‐Qaoud, Scott E. Eggener, John Richgels, George J. Chang, Cristina B. Geltzeiler, Gonzalo Sapisochín, Rocco Ricciardi, Alexander S. Krupnick, Cassie C. Kennedy, Nisha Mohindra, David P. Foley, Kymberly D. Watt - American Journal of Transplantation 2020 cited by 157

  24. Lenalidomide Combined With R-CHOP Overcomes Negative Prognostic Impact of Non–Germinal Center B-Cell Phenotype in Newly Diagnosed Diffuse Large B-Cell Lymphoma: A Phase II Study

    Authors: Grzegorz S. Nowakowski, Betsy LaPlant, William R. Macon, Craig B. Reeder, James M. Foran, Garth D. Nelson, Carrie A. Thompson, Candido E. Rivera, David J. Inwards, Ivana N. Micallef, Patrick B. Johnston, Luis F. Porrata, Stephen M. Ansell, Randy D. Gascoyne, Thomas M. Habermann, Thomas E. Witzig - Journal of Clinical Oncology 2014 cited by 364